Stock 688073 BIDE PHARMATECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bide Pharmatech Co., Ltd.

Equities

688073

CNE100005NV3

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-28 EDT 		5-day change 1st Jan Change
32.77 CNY +0.12% Intraday chart for Bide Pharmatech Co., Ltd. -3.93% -40.95%
04-25 Bide Pharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-02 Tranche Update on Bide Pharmatech Co., Ltd.'s Equity Buyback Plan announced on December 9, 2023. CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 5,333 5,044 2,977 - -
Enterprise Value (EV) 1 5,333 5,044 2,977 2,977 2,977
P/E ratio 29.7 x 45.9 x 14.9 x 10.2 x 14.2 x
Yield - 1.62% - - -
Capitalization / Revenue 6.4 x 4.62 x 2.31 x 1.58 x 1.57 x
EV / Revenue 6.4 x 4.62 x 2.31 x 1.58 x 1.57 x
EV / EBITDA 28.6 x 33.6 x 11.3 x 8.19 x -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book 2.57 x 2.41 x 1.39 x 1.16 x 1.28 x
Nbr of stocks (in thousands) 90,883 90,883 90,883 - -
Reference price 2 58.68 55.50 32.77 32.77 32.77
Announcement Date 1/13/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 833.8 1,092 1,288 1,881 1,899
EBITDA 1 - 186.2 150.3 263.5 363.5 -
EBIT 1 - 171.7 126.6 156 344.8 246
Operating Margin - 20.6% 11.6% 12.11% 18.32% 12.96%
Earnings before Tax (EBT) 1 - 171.8 126 156 344.8 246
Net income 1 97.57 146 109.6 200.4 293.4 210.1
Net margin - 17.51% 10.04% 15.56% 15.6% 11.07%
EPS 2 1.457 1.979 1.210 2.205 3.228 2.310
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - 0.9000 - - -
Announcement Date 9/14/22 1/13/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - 14.2% 5.28% 8.77% 11.2% 9.04%
ROA (Net income/ Total Assets) - 8.94% - 5.2% 8.83% 7.4%
Assets 1 - 1,633 - 3,854 3,322 2,840
Book Value Per Share 2 - 22.80 23.00 23.60 28.30 25.60
Cash Flow per Share 2 - 0.3300 -0.6300 0.6500 1.110 -
Capex 1 - 38.4 60.2 57.7 33.7 36
Capex / Sales - 4.61% 5.51% 4.48% 1.79% 1.9%
Announcement Date 9/14/22 1/13/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bide Pharmatech Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
32.77 CNY
Average target price
41 CNY
Spread / Average Target
+25.11%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIDE PHARMATECH CO., LTD. Stock Bide Pharmatech Co., Ltd.
-40.95% 411M
MODERNA, INC. Stock Moderna, Inc.
+51.25% 56.69B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.26% 41B
LONZA GROUP AG Stock Lonza Group AG
+38.14% 38.11B
CELLTRION, INC. Stock Celltrion, Inc.
-11.22% 26.89B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.63% 25.59B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.82% 18.59B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.12% 12.39B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.93% 11.99B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.97% 11.88B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 688073 Stock
  4. Financials Bide Pharmatech Co., Ltd.